« Return to News | CROs/Service Providers

Charles River provides financial guidance for 2012

Thursday, December 15, 2011 02:59 PM

Charles River Laboratories International has provided guidance for 2012 and updated guidance for 2011. James C. Foster, Chairman, president and chief executive officer, said, “We made significant progress in 2011 on our four key initiatives, which include operating margin expansion, improved free cash flow, disciplined investment in existing growth businesses, and returning value to shareholders. In 2012, we will maintain our focus on these initiatives and on stimulating sales growth.”

“Our large biopharmaceutical clients are fundamentally rethinking their research processes; eliminating non-viable molecules earlier and focusing only on the most promising molecules. To further improve the efficiency and cost effectiveness of their research, they are increasingly choosing to outsource, particularly in the area of discovery services. Because of our expertise in in vivo biology, this is a significant opportunity for us, one on which we intend to capitalize," Foster added.

“We believe market conditions have stabilized, and visibility is improving. As a result, we view 2012 as a more stable year in which sales growth begins to strengthen in a range of 1% to 3% on a constant currency basis, and non-GAAP earnings per share increase between 7% and 11%, or in a range of $2.60 to $2.70," said Foster.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.